Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

J&J leans toward spinning off orthopaedics as medtech lags, pharma powers guidance raise

Published Oct 13, 2026
Share:
Summary:
  • Medtech grew 2.5% in Q3 and missed estimates, with international medtech sales largely flat and surgical devices down 3.4%.
  • CFO Joe Wolk: "Medtech needs to improve quite frankly," and management is "leaning toward a straight spin" of the orthopaedics unit.
  • Full-year adjusted EPS outlook lifted to $11.05 to $11.15 from $10.96 to $11.11 as newer drugs outperformed; overall revenue barely topped forecasts.

Quarter highlights and the medtech picture

Johnson & Johnson's device business inched ahead 2.5% in the third quarter, trailing its larger pharmaceuticals arm and coming up shy of expectations. International medtech sales were largely flat, and surgical devices slipped 3.4%. According to Joe Wolk, the company's finance chief, demand outside the US has been dampened by worldwide headwinds such as the war in the Middle East and budget-tightening in some European countries.

Wolk put it plainly: "Medtech needs to improve quite frankly." Analysts agreed the showing left something to be desired. RBC Capital Markets' Trung Huynh wrote, "This quarter did not materially advance the growth narrative," calling it "another lackluster Medtech quarter." Mizuho's Jared Holz said device performance looked weak "really across the board" and flagged it as "the area of most scrutiny today."

Orthopaedics review and deal talks

J&J is moving toward separating its orthopaedics unit via a spin rather than a sale. As Wolk put it, management is "leaning toward a straight spin" because "we think that's the greatest way to create value, and that's likely the path going forward."

Last month, Bloomberg said Apollo Global Management Inc. had been in talks about buying the division at close to a $20 billion valuation, with the caveat that negotiations might end without a deal. Orthopaedics has been a slower-growing slice of J&J's medtech business.

Spin-offs reveal which divisions a conglomerate no longer wants to fund. Market Briefs covers these breakups free every morning.

Pharma strength and company-level results

J&J's drug unit, which generates about twice the revenue of medtech, grew 7.7% from a year earlier. Standouts included Tremfya, up 68% and ahead of estimates; Caplyta, up 66% as prescriptions expanded to newer uses such as add-on therapy for depression; and Tecvayli, higher by nearly 77%. Darzalex increased at a double-digit rate but missed analyst projections. While sales for new psoriasis pill Icotyde are not yet broken out, Wolk said 20,000 people have received prescriptions.

Total revenue landed roughly in line with expectations, topping estimates by the slimmest margin in years. The company raised its full-year adjusted EPS outlook to $11.05 to $11.15 from $10.96 to $11.11, with the midpoint above analyst projections. As the first big pharma name to report each quarter, J&J often sets the tone, and Tuesday's results indicate drugmakers are adapting to federal policy shifts and recent leadership changes at the US Food and Drug Administration.

What investors should watch next

Inside devices, J&J is steering toward faster-growing niches. In July, the company secured FDA clearance for Ottava, its soft-tissue robotic surgical system, marking a step into the high-growth robotics category. Shares fell 3.7% at 9:32 a.m.

Tuesday in New York after the update, though through Monday's close they were up 38% over the prior year, versus a 19% rise for the S&P 500 Index. Also in the background: last quarter's device miss, tied partly to Abiomed's heart pump business, has investors watching the turnaround timeline.

Separating a unit usually unlocks value for one side only. Get the free Market Briefs daily newsletter and follow it.

Disclosure

Recent News

1 2 3 … 130

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 17, 2026
Is the Stock Market Going to Crash? Why Nvidia and the Fed Have Investors on Edge
  • Tech stocks are selling off because investors don't know who will lead Nvidia, the company that has been funding the AI industry and selling it chips.
  • Inflation has the Federal Reserve planning to raise interest rates, with a hike expected in December, and that puts pressure on homebuyers, private equity and the $40 trillion national debt.
  • Briefs Finance CEO Jaspreet Singh says nobody has a crystal ball, so his rules are to buy when markets are low, hold long term and invest only what you're willing to lose.
Read More
November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
November 14, 2026
Rare Earth Stocks: Why China's January 2027 Ban Could Be the Opportunity of the Decade
  • China plans to block rare earth exports to the US on January 10, 2027, and the US produces effectively zero of the 17 metals that go into phones, cars, dishwashers, and missiles.
  • When China cut off Japan in 2010 and squeezed Germany from 2015, some rare earth prices jumped 18x and 15x, and one rare earth company went bankrupt while another soared.
  • Washington is already putting billions into MP Materials, Vulcan, and a stockpile called Project Vault, and Jaspreet Singh walks through how investors can get exposure to rare earth stocks and ETFs.
Read More
1 2 3 … 33
Share via
Copy link